In Vivo CAR-t generation using an engineered lentiviral vector platform targeting BCMA, CD19 and CD20.
Year: 2025
Type: conference-abstract
Source: Blood
Authors: yongke zhang, yongkun yang, Jianwei Liu, huan he, lijuan hou, mu zhang, jianxin he, yuanyuan zhu, jianhua zhang, bang shaw, Jinhua Zhang
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108698947